Eribulin Mesylate Showed Treatment Activity in Advanced Breast Cancer

The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence of Grade 3 (severe) and no Grade 4 (disabling or life-threatening) neuropathy.

"The anti-tumor activity of eribulin mesylate, as observed in this study, is encouraging, given the limited treatment options for women with advanced breast cancer who have previously received multiple lines of therapy," said lead investigator Linda T. Vahdat, MD, of Weill Cornell Medical College in New York. "The subjects in this trial had received a median of four prior chemotherapy regimens that included an anthracycline, a taxane and capecitabine."

About Study 211

Study 211 is a Phase II, open-label, single-arm study evaluating the efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer who had received an anthracycline, a taxane and capecitabine as prior therapy, and who were refractory to their last chemotherapy regimen, as documented by progression on or within six months of that therapy.

Advertisement

Of 299 patients enrolled in the study, 291 were treated with eribulin mesylate. The median age of those patients was 56 years (range: 26-80 years). Eribulin mesylate was administered at a dose of 1.4mg/m2 as a 2- to 5-minute intravenous infusion on Days 1 and 8 of a 21-day cycle. Patients received a median of four cycles of eribulin mesylate (range 1-27). No premedication to prevent hypersensitivity was required.

The safety analysis included all 291 patients who received treatment with eribulin mesylate. Patients with up to Grade 2 peripheral neuropathy were included in the study. The most frequently reported Grade 3 (severe) or Grade 4 (disabling or life-threatening) adverse events were neutropenia (a decrease in the number of granular white blood cells, 54%); febrile neutropenia, 5.5%, leukopenia (low white blood cell count, 14%), and weakness/fatigue (10%; no Grade 4 events). Grade 3 peripheral neuropathy (a functional disturbance or damage to nerves outside the brain and spinal cord) was reported in 5.5% of patients. No Grade 4 peripheral neuropathy events were reported. No correlation was seen between Grade 2 peripheral neuropathy and deterioration.

"In this study, eribulin mesylate appeared to have an acceptable tolerability profile, particularly with regard to the low incidence of peripheral neuropathy," noted Vahdat. "None of the reported cases of neuropathy were disabling, suggesting that eribulin mesylate, if approved, may be a useful addition to the treatment armamentarium for advanced breast cancer."

Related Terms

When he was 13 years old, Julian Rios Cantu’s mother was diagnosed with cancer for the second time that almost took her life. This motivated Julian to investigate how to help patients with breast cancer and, after 2 years of research, he created a special bra attachment called Higia that can help in the early detection of breast cancer.

When scheduling my first mammogram, the administrative assistant asked me a series of questions, one of which was, "Have you ever had an abortion"? I asked if abortion was linked to breast cancer. Her reply, that surprised me, was "yes".

Endocrine disruptors are toxic chemicals found in a host of everyday items from household cleaning products to mattresses, but the sad truth is that many lurk in skincare products we put directly on our bodies every day.

If you've heard all the buzz about fermented foods, you should try out this Keto Miso Mushroom Soup recipe - ready to eat in just 11 minutes! Once you read about Miso Soup Health Benefits, and taste this creamy, dreamy mixture, that combines Miso with coconut milk, mushrooms and garlic, you will want to add it to your weekly menu.

About 1 in 8 U.S. women will develop invasive breast cancer over the course of her lifetime, and there is an estimated 252,710 new cases of invasive breast cancer expected to be diagnosed in women in the U.S, according to breast cancer.org. There has been extensive research linking the accumulation of aluminium on the area breast cancer develops. So, here we will have a look at what science says about the link, and learn how to prevent breast cancer by making your own aluminium free deodorant.